NICE first rejected Kadcyla back in 2014, saying its cost of around £91,000 per patient at full price was too high, and that a small discount was not enough for it to be considered cost effective.

Kadcyla was one of the most expensive drugs on the CDF, costing up to £65,000 per patients, and charity Breast Cancer Now took the unusual step of calling on Roche to lower its price.

Iksuda Therapeutics, a clinical stage and UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and ...

Get the latest Sonnet BioTherapeutics Holdings, Inc. (SONN) stock news and headlines to help you in your trading and investing decisions.

View today's Chugai Pharmaceutical Co., Ltd. stock price and latest 4519 news and analysis. Create real-time notifications to follow any changes in the live stock price.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.

Native mass spectrometry (MS) involves the analysis and characterization of macromolecules, predominantly intact proteins and protein complexes, whereby as much as possible the native structural ...

Site-selective chemical conjugation of synthetic molecules to proteins expands their functional and therapeutic capacity. Current protein modification methods, based on synthetic and biochemical ...